Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment

British Journal of Haematology

Volumn 153, Issue 3, 2011, Pages 379-385

  Teichert, Martina ^a,b   van Noord, Charlotte ^a   Uitterlinden, Andre G ^a   Hofman, Albert ^a   Buhre, Peter N ^c   De Smet, Peter A G M ^b,d   Straus, Sabine ^a,e   Stricker, Bruno H Ch ^a,f   Visser, Loes E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Scientific Institute Dutch Pharmacists   (Netherlands)

^c STAR Medical Diagnostic Center   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MEDICINES EVALUATION BOARD   (Netherlands)

^f Drug Safety Unit   (Netherlands)

Author keywords

Acenocoumarol; Esomeprazole; Lansoprazole; Omeprazole; Proton pump inhibitors

Indexed keywords

ACENOCOUMAROL; ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ADULT; AGED; ALLELE; ANTICOAGULATION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYP2C19 GENE; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT RESPONSE;

ACENOCOUMAROL; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; DRUG SYNERGISM; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 79954423810     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08633.x     Document Type: Article

References (41)

1. Aebeloe, A., Andersson, T., Antonsson, M., Naudot, A., Skanberg, I. & Weidolf, L. (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metabolism and Disposition.
2. Andersen, P. & Gill, R. (1982) Cox's regression model for counting processes: a large sample study. Annals of Statistics, 10, 110-112.
3. Andersson, T., Roehss, K., Bredberg, E. & Hassan-Alin, M. (2001) Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Alimentary Pharmacology & Therapeutics, 15, 1563-1569.
4. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. & Hylek, E. (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126, 204S-233S.
5. Aquilante, C.L., Langaee, T.Y., Lopez, L.M., Yarandi, H.N., Tromberg, J.S., Mohuczy, D., Gaston, K.L., Waddell, C.D., Chirico, M.J. & Johnson, J.A. (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clinical Pharmacology and Therapeutics, 79, 291-302.
6. Blume, H., Donath, F., Warnke, A. & Schug, B. (2006) Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety, 29, 769-784.
7. Cannegieter, S.C., Rosendaal, F.R., Wintzen, A.R., van der Meer, F.J.M., Vandenbroucke, J.P. & Briet, E. (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. New England Journal of Medicine, 333, 11-17.
8. Carlquist, J.F., Horne, B., Muhlestein, J., Lappé, D., Whiting, B., Kolek, M., Clarke, J., James, B. & Anderson, J. (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. Journal of Thrombosis and Thrombolysis, 22, 191-197.
9. D'Andrea, G., D'Ambrosio, R.L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. & Margaglione, M. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 105, 645-649.
10. Ehrlich, A., Fuder, H., Hartmann, M., Wieckhorst, G., Timmer, W., Huber, R., Birkel, M., Bliesath, H., Steinijans, V., Wurst, W. & Lücker, P. (1996) Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. European Journal of Clinical Pharmacology, 51, 277-281.
11. Enderle, C.M., Müller, W & Grass, U. (2001) Drug interaction: omeprazole and phenprocoumon. BMC gastroenterology, 1, BMC gastroenterology 1:2. Epub 2001 Apr 6.
12. Federatie van Nederlandse Trombosediensten (visited 28th September 2010) Interacterende medicatie cumarines. Available at: Accessed 18th of September 2010.
13. Flockhart, D., O'Kane, D., Williams, M., Watson, M., Gage, B., Gandolfi, R., King, R., Lyon, E., Nussbaum, R., Schulman, K., Veenstra, D., Williams, M., Watson, M. & ACMG Working Group on Pharmacogenetic Testing of CYP2C9, V.A.f.W.U. (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine, 10, 139-150.
14. Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L., Seifried, E., Muller, C.R., Wienker, T.F. & Oldenburg, J. (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thrombosis and Haemostasis, 94, 773-779.
15. Gerson, L. & Triadafiopoulos, G. (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. European Journal of Gastroenterology & Hepatology, 13, 611-616.
16. Hancock, D.B., Eijgelsheim, M., Wilk, J.B., Gharib, S.A., Loehr, L.R., Marciante, K.D., Franceschini, N., van Durme, Y.M.T.A., Chen, T.-h., Barr, R.G., Schabath, M.B., Couper, D.J., Brusselle, G.G., Psaty, B.M., van Duijn, C.M., Rotter, J.I., Uitterlinden, A.G., Hofman, A., Punjabi, N.M., Rivadeneira, F., Morrison, A.C., Enright, P.L., North, K.E., Heckbert, S.R., Lumley, T., Stricker, B.H.C., O'Connor, G.T. & London, S.J. (2010) Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nature Genetics, 42, 45-52.
17. Hata, M., Hayasaka, M., Sezai, A., Niino, T., Yoda, M., Unosawa, S., Taoka, M., Osaka, S., Furukawa, N., Kimura, H. & Minami, K. (2008) Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thoracic and Cardiovascular Surgeon, 56, 274-277.
18. Hofman, A., Grobbee, D.E., de Jong, P.T. & van den Ouweland, F.A. (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. European Journal of Epidemiology, 7, 403-422.
19. Hofman, A., Breteler, M., van Duijn, C., Krestin, G., Pols, H., Stricker, B., Tiemeier, H., Uitterlinden, A., Vingerling, J. & Witteman, J. (2007) The Rotterdam Study: objectives and design update. European Journal of Epidemiology, 22, 819-829.
20. Hofman, A., Breteler, M., Van Duijn, C., Janssen, H., Krestin, G., Kuipers, E., Stricker, B., Tiemeier, H., Uitterlinden, A., Vingerling, J. & Witteman, J. (2009) The Rotterdam Study: 2010 objectives and design update. European Journal of Epidemiology, 24, 553-572.
21. van der Hooft, C., Dieleman, J.P., Siemes, C., Aarnoudse, A.L.H.J., Verhamme, K.C., Stricker, B.H.C. & Sturkenboom, M.M. (2008) Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiology and Drug Safety, 17, 365-371.
22. de Hoon, J., Thijssen, H., Beysens, A. & van Bortel, L. (1997) No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 44, 399-401.
23. Hosmer, D. & Lemeshow, S. (1992) Confidence interval estimation of interaction. Epidemiology, 3, 452-456.
24. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (2008) Informatorium, Pharmacokinetics with Proton Pump Inhibitors. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, The Hague, the Netherlands.
25. Lareb Dutch National Pharmacovigilance Centre (2009) Omeprazole. Available at:, omeprazole and coumarine interactions. Accessed 18th of September 2010.
26. Leendertse, A., Egberts, A., Stoker, L. & Bemt van der, P. (2008) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Archives of Internal Medicine, 168, 1890-1896.
27. Li, X., Andersson, T. & Ahlstroem, M. (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabolism and Disposition, 32, 821-827.
28. McCarthy, D., McLaughlin, T., Griffis, D. & Yazdani, C. (2003) Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. American Journal of Therapeutics, 10, 330-340.
29. Oldenburg, J., Bevans, C., Fergin, A., Geisen, C., Müller-Reible, C. & Watzka, M. (2007) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thrombosis and Haemostasis, 98, 570-578.
30. Qazim, B., Stöllberger, C., Krugluger, W., Dossenbach-Glaninger, A. & Finsterer, J. (2009) Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. Journal of Thrombosis and Haemostasis, 28, 211-214.
31. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K. & Kamali, F. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 2329-2333.
32. Simon, W. (2003) Faster in vitro biotransformation of S-omeprazole by the cytochrome P450 isoenzyme system compared to pantoprazole. Pharmacotherapy, 23, 1338.
33. Stricker, B. & Steijnen, T. (2010) Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. European Journal of Epidemiology, 25, 245-251.
34. Sutfin, T., Balmer, K., Boström, H., Eriksson, S., Höglund, P. & Paulsen, O. (1989) Stereoselective interaction of omeprazole with warfarin in healthy men. Therapeutic Drug Monitoring, 11, 176-184.
35. Teichert, M., Eijgelsheim, M., Rivadeneira, F., Uitterlinden, A., van Schaik, R., Hofman, A., de Smet, P., van Gelder, T., Visser, L. & Stricker, B. (2009) A genome-wide association study of acenocoumarol maintenance dosage. Human Molecular Genetics, 18, 3758-3768.
36. Unge, P., Svedberg, L., Nordgren, A., Blom, H., Andersson, T., Lagerström, P. & Idström, J. (1992) A study of the interaction of omeprazole and warfarin in anticoagulated patients. British Journal of Clinical Pharmacology, 34, 509-512.
37. Visser, L.E., van Schaik, R.H.N., van Vliet, M., Trienekens, P.H., De Smet, P.A.G.M., Vulto, A.G., Hofman, A., van Duijn, C.M. & Stricker, B.H.C. (2005) Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clinical Pharmacology and Therapeutics, 77, 479-485.
38. Vreeburg, E., de Vlaam-Schluter, G., Trienekens, P., Snel, P. & Tytgat, G. (1997) Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scandinavian Journal of Gastroenterology, 32, 991-994.
39. Wells, S., Holbrook, A., Crowther, N. & Hirsh, J. (1994) Interactions of warfarin with drugs and food. Annals of Internal Medicine, 121, 676-683.
40. World Health Organization Collaborating Centre for Drug Statistics Methodology (2004) Guidelines for ATC Classification and DDD Assignment. World Health Organization Collaborating Centre for Drug Statistics Methodology, Oslo.
41. Yang, J. & Link, C. (2010) CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opinion on Drug Metabolism & Toxicology, 6, 29-41.